Literature DB >> 12684928

Safety of voriconazole and dose individualization.

Irja Lutsar, Mike R Hodges, Konrad Tomaszewski, Peter F Troke, Nolan D Wood.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684928     DOI: 10.1086/374248

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  24 in total

1.  Does one voriconazole breakpoint suit all Candida species?

Authors:  Maiken Cavling Arendrup; David W Denning; M A Pfaller; D J Diekema; J H Rex
Journal:  J Clin Microbiol       Date:  2007-06       Impact factor: 5.948

Review 2.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

4.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

5.  Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.

Authors:  Michael A Thiel; Annelies S Zinkernagel; Jürgen Burhenne; Claude Kaufmann; Walter E Haefeli
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

6.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

7.  Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.

Authors:  I Amigues; N Cohen; D Chung; S K Seo; C Plescia; A Jakubowski; J Barker; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-09       Impact factor: 5.742

8.  Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.

Authors:  Emma Andrews; Bharat D Damle; Annie Fang; Grover Foster; Penelope Crownover; Robert LaBadie; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

Review 9.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.